Background-Findings from clinical trials and population-based studies have differed as to whether mortality within 30 days of diagnosis (early death) of acute promyelocytic leukemia has decreased in the era of all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy.
INTRODUCTION
Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) that carries the PML/RAR-α fusion in more than 90% of cases. Bleeding and thrombosis are frequent and can be aggravated by cytotoxic chemotherapy, resulting in early death due mainly to intracranial hemorrhage. 1 An estimated 600-800 new cases of APL (4%-13% of AML cases) occur annually in the U.S., most frequently in adults. 2, 3 While APL was once highly fatal, the addition of alltrans retinoic acid (ATRA) to anthracycline-based chemotherapy and the introduction of arsenic trioxide (arsenic) have dramatically improved outcomes; currently, 95%-100% of patients with APL gain complete remission. 4, 5 Moreover, arsenic has become the treatment of choice for relapsed APL after frontline treatment with ATRA and chemotherapy. 6 ATRA and arsenic rapidly reduce the risk of hemorrhage and should be initiated as soon as APL is suspected. 7 ATRA was approved by the U.S. Food and Drug Administration (FDA) in November, 1995 and arsenic in September, 2000. During the ATRA era, early death has decreased overall, from approximately 20% 8, 9 to 5%-10%. 10 However, early death remains high in the U.S. 11, 12 and Europe, 13 implicating factors other than ATRA.
Because recent studies have examined early death and survival in patients aged ≥15 years 11, 13, 14 and there are few reports of population-based studies in young patients with APL (Supplementary Table S1 ), we investigated early death and survival in patients in California, diagnosed at ages 0-39 years over a 25-year period, and assessed the association of sociodemographic and clinical factors with these outcomes.
2012. APL was diagnosed as histology code 9866 in the International Classification of Diseases for Oncology, third edition. 16 Of 784 patients identified, 4 were excluded due to missing date of diagnosis and 8 due to unknown or Native American (small subgroup) race/ ethnicity. Our study included 772 patients.
Variables
The variables examined for association with APL outcomes were age at diagnosis, categorized as four groups based on progressive decrements in survival 17 18 Information on hospital designation was from the initial reporting facility. There were no data on intensity of treatment or drugs used (conventional genotoxic chemotherapy, ATRA and/or arsenic).
Statistical analysis
We used univariable and multivariable logistic regression to investigate the association of the sociodemographic and clinical factors with 7-and 30-day mortality, through estimation of the odds ratios (ORs) and associated 95% confidence intervals (CIs). We analyzed 30-day mortality with and without patients who died within 7 days. We estimated overall survival (all-cause survival) at 1 and 5 years by using the Kaplan-Meier method, and compared differences in survival across strata for each variable using the log-rank test. We used univariable and multivariable Cox regression models to examine the association of sociodemographic and clinical factors with the risk of death, through estimation of the hazard ratios (HRs) and associated 95% CIs. Schoenfeld residuals were used to assess the proportional hazard assumptions. We tested for interactions between calendar periods, age groups, neighborhood SES and race/ethnicity. All statistical analyses we performed by using the Stata 13 software. A two-sided P<0.05 was considered statistically significant.
Early death
Among patients who experienced early death, median age at diagnosis was 29 years; 82 of these patients (11%) died within 7 days and 133 (17%) died within 30 days of diagnosis. Thirty-day mortality decreased significantly over the 3 eras from 26% in 1988-1995 (pre-ATRA) to 16% in 1996-2003 (earlier ATRA era) to 14% in 2004-2011 (later ATRA era) (P=0.004, Table 1 ) (Figure 1 ). However, 7-day mortality showed no evidence of a significant decrease. In a multivariable analysis ( Table 1 ). Based on the log-rank test, a lower survival estimate was significantly associated with earlier period of diagnosis, male sex, older age at diagnosis, and lack of health insurance ( Table 1) . In univariable analyses, survival was lower in Hispanic and black vs. white patients and uninsured vs. insured patients. In multivariable models, the 1988-1995 era, black/Hispanic race/ethnicity and lack of health insurance remained significantly associated with the hazard of death (Table 3) . There was no evidence of a difference in HR between patients with private vs. public insurance (P=0.999). There was no evidence of violation of the Cox proportional hazard assumptions or of interactions between any variables.
When we excluded patients who died within 30 days of diagnosis in 1996-2011, 5-year survival increased from 77.8% (95% CI: 70.7%-83.3%) to 88.8% (95% CI: 82.4%-93.0%) among patients aged 0-19 years, and from 72.5% (95% CI: 67.8%-76.6%) to 86.3% (95% CI: 81.9%-89.7%) among patients aged 20-39 years (data not shown).
DISCUSSION
In our population-based study spanning 25 years, 30-day mortality decreased significantly after 1995, coinciding with the introduction of ATRA and guidelines recommending aggressive blood product support and intensive infection prophylaxis and treatment for suspected APL. Nevertheless, 30-day mortality remained higher than that observed in non-APL subtypes of AML, 19 and 7-day mortality did not improve over time. Our findings suggest that factors other than ATRA contributed to early death; these may include the timing of diagnosis or chemotherapy, hospital availability of ATRA/arsenic during the critical 2-3 days after diagnosis, adequate blood products and infection prophylaxis and treatment. A recent study of randomly selected hospitals in the U.S. found that less than half had ATRA, and one of the main barriers to availability was the absence of ATRA on their formularies. 20 Patients who suffered early death probably lacked early access to effective treatment and/or were too ill when admitted; ten patients in this study died on the day of diagnosis. The FDA's approval of ATRA (and later, arsenic) may not have resulted in the wide or timely availability of these drugs across all California hospitals.
Moreover, despite the great effectiveness of ATRA and arsenic, treatment may cause severe complications that should be recognized and treated promptly, such as differentiation syndrome. Differentiation syndrome occurs in about 2%-31% of patients receiving induction therapy and can mimic other severe complications, such as pulmonary hemorrhage, renal dysfunction and heart failure. 21 Because of the abrupt presentation and potential gravity of differentiation syndrome, preemptive use of corticosteroids has been proposed. 22 The syndrome may be promoted by delaying chemotherapy after ATRA, 23 and delaying ATRA itself for more than 2 days may increase the risk of fatal hemorrhage. 24 These findings confirm the importance of early diagnosis, rapid intensive treatment and adequate supportive care.
Importantly, we found that uninsured patients had a higher risk of early death and lower survival estimates than those with private and public insurance, suggesting lack of adequate access to care. Our results are consistent with a previous report of worse survival in uninsured vs. insured AYAs. 25 Wider insurance coverage is likely to provide better outcomes for these patients. Additionally, early death was higher among Hispanic patients, and survival was lower among black and Hispanic patients, than those among white patients. Similar findings have been reported in children with acute lymphoblastic leukemia (ALL), 26, 27 children with AML (excluding APL) 28 and adults with AML (including APL). 14 To provide effective and sustainable treatment to patients with APL -a severe but highly curable disease -efforts should also address the social contributors to health inequity, 29 such as poverty, inadequate access to transportation, and lack of education resources.
In general, population-based studies, 11, 12 such as ours, show a greater proportion of early death than do multi-institutional protocols. The differing findings may reflect the exclusion of patients who died during the first week or were too ill for chemotherapy in prior studies. 30 In our study, when we excluded deaths within 7 days, we found 30-day mortality during the ATRA era to approximate that in clinical trials. 10, 31 Similarly, when we excluded patients who died within 30 days of diagnosis, 5-year survival was close to that reported in multi-institutional trials in children and AYAs. 32, 33 These observations suggest that selection bias may contribute to the differences in reported survival and early death between most clinical trials and population-based studies.
Our study had several limitations. Hospital designation was limited to the location of initial care at the reporting facility, so it is possible that some patients diagnosed at one type of facility were subsequently treated at another. However, 92% of our patients received at least part of their treatment at this hospital, suggesting that our findings were not substantially influenced by this factor. We also lacked data on patients' risk classification at diagnosis, laboratory data, and blood products administered. Although this information would likely have contributed additional important findings, disease outcomes such as early death and survival are of paramount concern. Survival is a measure of the cancer burden and the health system effectiveness and plays a key role in the development of health policies. 34 Our large California APL cohort allowed us to compare early death and survival across treatment eras and investigate sociodemographic factors associated with outcome. To our knowledge, this is the first population-based study to investigate the association of race/ethnicity with early death and survival in children with APL and to consider the association of outcome with health insurance, hospital type, age, sex, treatment era and neighborhood SES. Further, unlike previous population-based studies, 11, 12, 19 we were able to assess 7-day mortality.
In conclusion, our findings indicate a true reduction of 30-day mortality among children and AYAs with APL in California, suggesting adherence to modern therapeutic strategies. However, 7-day mortality remained high, suggesting that factors other than ATRA played a role in early death. We identified subgroups of patients vulnerable to early death and reduced survival, including the uninsured and Hispanic patients. Black patients also experienced worse survival. To improve outcomes among young patients with APL, efforts should focus on improving access to effective treatment, mainly among uninsured patients and those of Hispanic and Black race/ethnicity.
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